178 related articles for article (PubMed ID: 34033706)
1. Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation.
Antos NJ; Savant AP
Pediatr Pulmonol; 2022 Feb; 57(2):347-360. PubMed ID: 34033706
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
3. Review of CFTR modulators 2020.
Goetz DM; Savant AP
Pediatr Pulmonol; 2021 Dec; 56(12):3595-3606. PubMed ID: 34407318
[TBL] [Abstract][Full Text] [Related]
4. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
6. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
Edmondson C; Course CW; Doull I
Arch Dis Child; 2021 Oct; 106(10):941-945. PubMed ID: 33785533
[TBL] [Abstract][Full Text] [Related]
8. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
9. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
10. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations.
Munck A; Kerem E; Ellemunter H; Campbell D; Wang LT; Ahluwalia N; Owen CA; Wainwright C
J Cyst Fibros; 2020 Nov; 19(6):962-968. PubMed ID: 32546431
[TBL] [Abstract][Full Text] [Related]
11. Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis.
Lyman BC; Seay J; Contreary C; Savant AP; Dell ML; Hescock GC
Pediatr Pulmonol; 2022 Dec; 57(12):3174-3176. PubMed ID: 35962539
[No Abstract] [Full Text] [Related]
12. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
Hoy SM
Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
[TBL] [Abstract][Full Text] [Related]
13. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
[TBL] [Abstract][Full Text] [Related]
14. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
15. Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.
Jordan KD; Zemanick ET; Taylor-Cousar JL; Hoppe JE
Expert Rev Respir Med; 2023 Feb; 17(2):97-108. PubMed ID: 36803356
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
[TBL] [Abstract][Full Text] [Related]
17. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
18. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?
Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E
Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
20. Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis.
De Vuyst RC; Bennard E; Kam CW; McKinzie CJ; Esther CR
Pediatr Pulmonol; 2023 May; 58(5):1592-1594. PubMed ID: 36718851
[No Abstract] [Full Text] [Related]
[Next] [New Search]
